Sessions will start around 1535hrs
Medtronic |
Emerging options to manage uncontrolled hypertension: An update |
Sanofi |
LIVE Debate: Managing symptomatic CHD: “Treat the plaque” Vs “Treat the patient” |
Sessions will start around 1005hrs
Novartis |
Lp(a) – what is it, who to test and why |
Sessions will start around 1035hrs
Abbott |
See Simply. Act Decisively’, ANZ launch of Ultreon™ 1.0 Software, powered by AI |
Bio-Excel |
The Role of Heterotopic CAVI using TricValve for Tricuspid Regurgitation and other |
Medtronic |
Emerging options to manage uncontrolled hypertension: An update |
Sessions will start around 1505hrs
AstraZeneca |
Appropriate use of P2Y12 post-Acute MI. Are we doing the right thing?” |
Novartis |
Assessing the CRR performance of Entresto in the real world |